ASXC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ASXC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Asensus Surgical's Capital Expenditure for the three months ended in Dec. 2023 was $-0.07 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $-13.37 Mil.
GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.
The historical data trend for Asensus Surgical's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asensus Surgical Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
Asensus Surgical Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Capex-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Medical Devices subindustry, Asensus Surgical's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Asensus Surgical's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Asensus Surgical's Capex-to-Operating-Cash-Flow falls into.
Asensus Surgical's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (-0.561) | / | -63.627 | |
= | N/A |
Asensus Surgical's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as
Capex-to-Operating-Cash-Flow | = | - Capital Expenditure | / | Cash Flow from Operations |
= | - (-0.073) | / | -13.374 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asensus Surgical (AMEX:ASXC) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Thank you for viewing the detailed overview of Asensus Surgical's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Starling William N Jr | director | 2300 BUCKSKIN ROAD, POCATELLO ID 83201 |
Andrea Biffi | director | C/O SOFAR SPA, VIA FIRENZE 40, TREZZANO ROSA (MI) L6 20060 |
Elizabeth Kwo | director | C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
David Bruce Milne | director | ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108 |
Kevin J Hobert | director | 343 STATE STREET, ROCHESTER NY 14650 |
Fernando Anthony C. J. | officer: Chief Technology Officer | 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560 |
Rampertab Shameze | officer: EVP, Chief Financial Officer | C/O ZOMEDICA PHARMACEUTICALS CORP., 3928 VARSITY DRIVE, ANN ARBOR MI 48108 |
Brett Farabaugh | officer: Interim CFO | 108 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709 |
Joseph P Slattery | officer: EVP and CFO | C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560 |
Eric A Smith | officer: Chief Commercial Officer | 7 CALEB CIRCLE, SAN ANTONIO TX 78258 |
Todd Pope | director, officer: President and CEO | C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713 |
Willam N Kelley | director | MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889 |
Pfenniger Richard C Jr | director | 4400 BISCAYNE BLVD., MIAMI FL 33137 |
Sofar, S.p.a | 10 percent owner | VIA FIRENZE 40, TREZZANO ROSA L6 20060 |
Andrew N Schiff | director, 10 percent owner | PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022 |
From GuruFocus
By Barry Cohen Barry Cohen • 12-23-2020
By PRNewswire PRNewswire • 01-11-2021
By GuruFocusNews GuruFocusNews • 07-08-2022
By GF Value GF Value • 05-16-2021
By PRNewswire PRNewswire • 01-05-2021
By GuruFocusNews GuruFocusNews • 06-28-2022
By PRNewswire PRNewswire • 05-27-2021
By PRNewswire PRNewswire • 07-28-2021
By GF Value GF Value • 04-01-2021
By PRNewswire PRNewswire • 03-19-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.